|Webcasts|December 7, 2020

How Unified Insight Into Live Data Helped One Sponsor Succeed Where Many Others Failed

***Live: Monday, December 7, 2020 at 2pm EST | 1pm CST | 11am PST***Discover how a North American pharmaceutical company succeeded where dozens of trial sponsors had failed. Leveraging innovative new clinical software, the company helped transition its breakthrough science into trial success, by delivering consistently impeccable data that accelerated the program with far less cost and effort – ultimately leading to a successful submission***On demand available after final airing until Dec. 7, 2021***

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/unified_insight​

Event Overview: In this case study webinar, we explore how a North American pharmaceutical company’s innovative development program for an autoimmune disease treatment succeeded, when more than 30 drugs from other sponsors for the same indication had failed.

The key? Identifying specific medical, operational and logistical risks in the study, and then implementing analytic and workflow tools flexible enough to support tailored risk mitigation strategies – and robust enough to easily and cost-effectively aggregate ALL clinical and operational data from EDC, labs, safety systems, and more into a single unified view, regardless of data type or source. By giving researchers timely, direct access to high-value visualizations and early observations across every aspect of the study, with minimal effort through supporting workflows, the company was able to:

  • Accelerate clinical development and reduce patient and operational risk, including avoiding a clinical hold, by streamlining eligibility checking, medical monitoring, and DSMB/CEC communications with rapid access to high-quality data and detailed reporting
  • Convincingly demonstrate the drug’s benefit-risk profile to the FDA, with the agency accepting a Phase 2 study as pivotal - saving $50 million in development costs and reducing timelines by several months
  • Free key study personnel from heavy manual effort through automated data flows and reconciliations, for example conducting a successful rolling NDA submission through auto-generated patient profiles/narratives

Key Learning Objectives:

  • Explore the key challenges to easily and cost-effectively supporting risk mitigation strategies in studies with data integration and analytics, and how study teams are effectively overcoming these obstacles
  • Review how trial sponsors are obtaining a far clearer understanding of what their drugs are doing in the indication while the study is underway, without increasing alpha-spend

Examine the reasons behind the myth that it is too difficult and costly to achieve a single, unified view across a study or program from all clinical and operational data sources

Speaker: Patrick Keenan, Chief Strategist, Prevail InfoWorks

Time and Date: Monday, December 7, 2020 at 2pm EST | 1pm CST | 11am PST

On demand until Dec. 7 2021.

Sponsor: Prevail InfoWorks

Register Free: ​https://www.appliedclinicaltrialsonline.com/act_w/unified_insight​


Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.